You are here

Novartis

Novartis pads Cosentyx's psoriatic arthritis lead with joint-damage label update

Novartis pads Cosentyx's psoriatic arthritis lead with joint-damage label update

Fierce Pharma

psoriatic arthritis

Flag link:

5 Experimental New Drugs That Could Be Worth $47 Billion

5 Experimental New Drugs That Could Be Worth $47 Billion

Motley Fool

VX-659 + tezacaftor + ivacaftor

Vertex Pharmaceuticals

Flag link:

Novartis touts effectiveness, safety of autoimmune drug copies

Novartis touts effectiveness, safety of autoimmune drug copies

Yahoo/Reuters

autoimmune disease

Flag link:

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

Pharmaforum

ankylosing spondylitis

Flag link:

Is the future of therapy online? Swiss drug giant Novartis thinks so

Is the future of therapy online? Swiss drug giant Novartis thinks so

Marketwatch

Pear Therapeutics

digital therapeutics

Flag link:

Swiss Won’t Investigate Novartis Over Payments to Cohen

Swiss Won’t Investigate Novartis Over Payments to Cohen

Bloomberg

Flag link:

Migraine Breakthrough: Not So Fast

Migraine Breakthrough: Not So Fast

Forbes

monoclonal antibodies

Flag link:

ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?

ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?

Fierce Pharma

metastatic breast cancer

HER2-negative breast cancer

Flag link:

NTC acquires part of Novartis’ ophthalmic portfolio

NTC acquires part of Novartis’ ophthalmic portfolio

GoinPharma

Flag link:

How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales

How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales

Investors Business Daily

Flag link:

Novartis receives EU approval for biosimilar Zessly

Novartis receives EU approval for biosimilar Zessly

Reuters

Flag link:

Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200

Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200

Fierce Pharma

drug manufacturing

Flag link:

Cohen scandal disrupts ex-Novartis CEO's move to hedge fund board: WSJ

Cohen scandal disrupts ex-Novartis CEO's move to hedge fund board: WSJ

Fierce Pharma

Flag link:

Breast Cancer Cells Use In-House Recycling To Survive After Spreading

Breast Cancer Cells Use In-House Recycling To Survive After Spreading

Forbes

metastatic breast cancer

Flag link:

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

CNBC

Flag link:

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

Stat

Flag link:

Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?

Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?

Fierce Pharma

Flag link:

FDA calls out 39 drug companies for allegedly blocking access to generics

FDA calls out 39 drug companies for allegedly blocking access to generics

Stat

Valeant Pharmaceuticals

Flag link:

Former Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 Million

Former Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 Million

Forbes

Flag link:

Novartis chief lawyer departing over company’s payments made to Cohen

Novartis chief lawyer departing over company’s payments made to Cohen

Stat

Flag link:

Pages